Donepezil News and Research

RSS
Donepezil is a drug that is used to treat Alzheimer disease and is being studied in the treatment of side effects caused by radiation therapy to the brain. It is a type of cholinesterase inhibitor.
Investigational drug focuses on slowing Alzheimer's disease progression

Investigational drug focuses on slowing Alzheimer's disease progression

Forest Laboratories plans to discontinue sale of NAMENDA 5 mg and 10 mg tablets

Forest Laboratories plans to discontinue sale of NAMENDA 5 mg and 10 mg tablets

Mannotriose regulates learning and memory signal transduction in hippocampus

Mannotriose regulates learning and memory signal transduction in hippocampus

Study: Alpha tocepherol, fat-soluble vitamin E, antioxidant may slow functional decline in AD patients

Study: Alpha tocepherol, fat-soluble vitamin E, antioxidant may slow functional decline in AD patients

Merck provides update on MK-8931 investigational oral therapy for Alzheimer’s disease

Merck provides update on MK-8931 investigational oral therapy for Alzheimer’s disease

Lundbeck, Otsuka to continue development of Lu AE58054 compound for Alzheimer's disease

Lundbeck, Otsuka to continue development of Lu AE58054 compound for Alzheimer's disease

Adamas Pharmaceuticals reports positive results from ADS-5102 Phase 2/3 EASED clinical trial

Adamas Pharmaceuticals reports positive results from ADS-5102 Phase 2/3 EASED clinical trial

El Lilly calls for Medicare coverage of beta-amyloid imaging agents for Alzheimer's disease

El Lilly calls for Medicare coverage of beta-amyloid imaging agents for Alzheimer's disease

Anavex invited to submit funding application for Phase 2a trial of ANAVEX 2-73

Anavex invited to submit funding application for Phase 2a trial of ANAVEX 2-73

Lundbeck, Otsuka reach agreement to develop and commercialize Lu AE58054

Lundbeck, Otsuka reach agreement to develop and commercialize Lu AE58054

New research provides better understanding of preserving brain's functions while killing cancer

New research provides better understanding of preserving brain's functions while killing cancer

Countering neuroinflammation is indeed a potential therapeutic strategy for Alzheimer's

Countering neuroinflammation is indeed a potential therapeutic strategy for Alzheimer's

Study may spur research into multi-model imaging based biomarker development for AD

Study may spur research into multi-model imaging based biomarker development for AD

ASS234 molecule inhibits aggregation of the Alzheimer's protein

ASS234 molecule inhibits aggregation of the Alzheimer's protein

Adamas to present update on Nurelin program at CHI Targeting Parkinson's Disease Symposium

Adamas to present update on Nurelin program at CHI Targeting Parkinson's Disease Symposium

Breckenridge finalizes agreement with Huahai to market Nevirapine Tablets

Breckenridge finalizes agreement with Huahai to market Nevirapine Tablets

TPU, Eisai amend Aricept patch licensing agreement

TPU, Eisai amend Aricept patch licensing agreement

Patients with advanced Alzheimer’s benefit from drugs: Study finds

Patients with advanced Alzheimer’s benefit from drugs: Study finds

Pfizer, Medivation report results from dimebon Phase 3 trial on AD

Pfizer, Medivation report results from dimebon Phase 3 trial on AD

AstraZeneca plans to progress Targacept's AZD1446 as treatment for AD

AstraZeneca plans to progress Targacept's AZD1446 as treatment for AD

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.